DiaMedica Therapeutics (DMAC) Receivables - Accured (2019 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Receivables - Accured of $285000.0 for Q1 2026, up 24.45% year-over-year from $229000.0 in Q1 2025, and up 14.0% quarter-over-quarter from $250000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Receivables - Accured (2019 - 2026) Analysis & Trends
DiaMedica Therapeutics' Receivables - Accured history runs 8 years deep, the most recent figure standing at $285000.0 for Q1 2026.
- In Q1 2026, Receivables - Accured rose 24.45% year-over-year to $285000.0; the TTM figure through Mar 2026 stood at $285000.0 (up 24.45% YoY), while the FY2025 annual figure was $250000.0, up 6.38% from the prior year.
- Receivables - Accured for Q1 2026 stood at $285000.0, up from $250000.0 in the prior quarter.
- The five-year high for Receivables - Accured was $391000.0 in Q1 2024, with the low at $55000.0 in Q1 2023.
- The 5-year median for Receivables - Accured is $229000.0 (2025), against an average of $217058.8.
- The sharpest annual moves came in 2022 and 2023: Receivables - Accured soared 877.78% in 2022, then slumped 66.87% in 2023.
- DiaMedica Therapeutics' Receivables - Accured stood at $80000.0 in 2022, then jumped by 272.5% to $298000.0 in 2023, then decreased by 21.14% to $235000.0 in 2024, then grew by 6.38% to $250000.0 in 2025, then climbed by 14.0% to $285000.0 in 2026.
- Business Quant data shows DMAC's Receivables - Accured at $285000.0 in Q1 2026, $250000.0 in Q4 2025, and $228000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 236,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236,000.00 |
| Jun 30, 2026 | 236,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 250,000.00 |
| Dec 31, 2025 | 250,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Mar 31, 2024 | 391,000.00 |
| Mar 31, 2024 | 391,000.00 |